PCM
VERV

Prelude Capital Management’s Verve Therapeutics VERV Stock Holding History

Prelude Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,718
Closed -$345K – 1399
2025
Q2 		$345K Buy
+30,718
New +$175K 0.03% 559

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Prelude Capital Management's VERV Position: Q3 2025 in Review

Prelude Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 30,718 shares — an estimated $345K sold.

Prelude Capital Management first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $345K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Prelude Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 30,718 Verve Therapeutics shares in Q3 2025, an estimated $345K.
  • Prelude Capital Management first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Prelude Capital Management's Verve Therapeutics position peaked at $345K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.